The global celiac disease market is anticipated to grow significantly at a CAGR of 8.5% during the forecast period. Celiac disease is a digestive disorder in which the body has trouble absorbing nutrients such as lipids, calcium, iron, and folate. It is an autoimmune illness induced by eating gluten, which damages the small intestine's inner lining. Several diseases and conditions, including neurological abnormalities, infertility, reduced bone density, and some cancers, can be caused by the disease. People with type 1 diabetes, down syndrome, autoimmune thyroid disease, microscopic colitis, Addison's disease, and rheumatoid arthritis are at risk for this hereditary condition. Besides, the market for celiac disease therapy is predicted to rise significantly in the forecast period, owing to the development of several anti-inflammatory medications and therapeutic vaccinations that will replace or enhance a gluten-free diet.

The organization of various awareness programs and initiatives taken by the government in various nations for the treatment of celiac disease is a major factor that is driving the growth of the global celiac disease market. With such actions, the government may significantly stimulate market growth. Furthermore, numerous funds are available for R&D operations, which is propelling market expansion. For instance, in 2015, in Italy, children and adults with certain symptoms are tested for celiac disease. Diagnosed celiacs are given vouchers worth up to $168 per month to spend on specially made gluten-free meals. Furthermore, restaurants are educated on how to deal with celiac disease by the Italian Celiac Association and the government. Gluten-free meals are even available at hospitals, schools, and other public eating facilities.

Impact of COVID-19 Pandemic on Global Celiac Disease Market

The global celiac disease market is hit by the COVID-19 pandemic in December 2019. The excruciating need to screen and test large numbers of patients for potential SARS-Cov-2 infection is the most common problem for governments in all COVID-19-affected countries. As the new virus's rapid spread continues to affect communities around the globe, celiac disease susceptibility and risk levels have become a source of concern for the celiac community. The limits imposed to combat COVID-19 may have an impact on celiac disease treatment and gluten-free eating, which is now the sole treatment option for celiac disease. Apart from it, major players were focusing on the clinical trials for the celiac disease therapies, due to the pandemic trials was suspended and impacted negatively on the market growth. The market will witness “V” shape recovery in near future owing to the restart of activities in major economies.

Segmental Outlook 

The global celiac disease market can be segmented based on treatment type, diagnostic type, and end-user. Based on the treatment type, the market is classified into vitamins and dietary (gluten-free) supplements, steroids, and immunosuppressive drugs, and therapeutic vaccines. Based on the diagnostic type, the market is classified into the serologic test, genetic testing, and small-bowel biopsy. Apart from it, based on the end-user, the market is bifurcated into hospitals & diagnostics centers, and research institutes. 

Global Celiac Disease Market Share by Treatment Type, 2020 (%)

Vitamins and Dietary (Gluten-Free) Supplements Segment holds the significant share in the Global Celiac Disease Market 

Among the treatment type for the global celiac disease market, the vitamins and dietary (gluten-free) supplements segment held the highest share in 2020 and is also anticipated to grow significantly during the forecast period. For the treatment of celiac disease, no one pharmaceutical treatment or cure has been approved. As the only treatment option for celiac disease, the gluten-free diet segment is expected to grow. Bakery items, baby food, pasta, and ready meals are all gluten-free products. However, the maintaining a gluten-free diet is difficult and accidental gluten cross-contamination is unavoidable, the researchers such as ImmunogenX are focusing on finding alternative treatment and, possibly a cure for the illness. The compounds bl-7010, larazotide acetate, and vedolizumab are among the most promising in the pipeline for celiac disease.

Regional Outlooks

The global celiac disease market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East and Africa, and Latin America).  North America has been predicted to dominate the global celiac disease market, followed by Europe. The growth is mainly attributed due to an increase in demand for advanced treatment, increased health care expenditure, and a high diagnosis rate.  For instance, according to the National Health Expenditure Accounts (NHEA), In 2019, US healthcare spending increased by 4.6 % to $3.8 trillion, or $11,582 per person. Health spending accounted for 17.7 % of the nation's Gross Domestic Product.

Global Celiac Disease Market Growth, by Region 2021-2027

Asia-Pacific is projected to have a considerable growth in the Global Celiac Disease Market

Asia-Pacific is anticipated to exhibit the significant growth in the global celiac disease market. In the region, countries such as China and India are the most promising economies in terms of growth. This is attributable to growing healthcare infrastructure and high government spending, as well as increasing celiac disease patient awareness and a larger patient pool. 

Market Players Outlook

The key players of the global celiac disease market include Abbott Laboratories, Eli Lilly & Co, Novartis AG, Johnson & Johnson, BioLineRx Ltd., Amgen Inc., Siemens AG, and Bayer AG among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2019, Bristol-Myers Squibb Co., has announced the acquisition of Celgene Corporation, a company that works in celiac disease treatment. This acquisition expands the product portfolio for Bristol company.

The Report Covers

• Market value data analysis of 2020 and forecast to 2027.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global celiac disease market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.